Latest news

Our press releases and latest news

Here you will always find the latest news about Cannamedical® Pharma.



Cologne  –  Cannamedical® Pharma GmbH has successfully imported the first two batches of homogeneous MedReleaf varieties to Germany. Cannamedical® is now selling one of the high-quality cannabis strains to pharmacies throughout Germany. Six other varieties will become available in the coming weeks.

“With the first successful import from Canada at the beginning of July 2018, Cannamedical® Pharma laid the foundation for a quality-oriented and nationwide supply of European patients,” explains Niklas Kouparanis, Sales Director of the Cologne-based company. “We see a steadily growing demand in our pharmacy network since the introduction of the cannabis law in Germany in March 2017.

The number of cannabis units dispensed by prescription throughout Germany, has increased almost fifty times since the first quarter of 2017 to the first quarter of 2018. The fact that we will continue to import extraordinarily large quantities of standardized medical cannabis to Europe is greatly added value, in particular for patients, but also for pharmacists & doctors and underlines the company’s high level of professionalism as an established wholesaler. ”

Transparency, trust and reliability are among the core values of Cannamedical® Pharma. As a special service, and a first in Germany, doctors and pharmacists now have the opportunity to obtain information about the respective cannabinoid and terpene profile for each MedReleaf variety from the Cologne based wholesaler

“Terpenes have been underestimated for a long time. Today, however, one can assume that they play an essential part in the medical mode of action and are therefore of great importance for the therapy recommendation, “explains Katrin Rinas, Medical Advisor at Cannamedical®.

MedReleaf is one of the few GMP and ISO 9001 certified cannabis manufacturers in North America that is able to produce continuous homogeneous cannabis varieties.

The cooperation of both companies ensures product of the highest quality combined with a comprehensive range of services. The supply agreement with the Canadian producer represents a decisive step for Cannamedical® towards a permanent and nationwide supply of medicinal cannabis. The standardized MedReleaf varieties have stable genetics and are distributed throughout Germany  exclusively by Cannamedical® Pharma GmbH.

David Henn, CEO of Cannamedical® Pharma, emphasizes, “With the successful import from Canada and the support we provided with MedReleaf’s GMP certification, we are definitely among the most influential medical cannabis wholesalers in Europe. We are constantly expanding this leading position within Europe, “says the managing director.

“We are in an ideal position to reliably supply new European markets that are opening up in the near future.”

Medical experts can get comprehensive advice from Monday to Friday from 8 am to 8 pm from the expert team of Cannamedical® Pharma GmbH.

Cannamedical®-Pharmacy Advice line: +49 (0) 221 / 999 852 – 25

Cannamedical®-Doctors Advice line: +49 (0) 221 / 999 852 – 60



MedReleaf Corp. (TSX:LEAF) (“MedReleaf” or the “Company”), Canada’s first and only ISO 9001 and ICH-GMP certified cannabis producer, today announced that it has entered into an agreement to become the largest supplier of medical cannabis products to Cannamedical Pharma GMBH (“Cannamedical”), a leading medical cannabis distributor to pharmacies in Germany. MedReleaf will provide Cannamedical with monthly exports of five of its premium strain varieties significantly improving the predictability and security of drug delivery to the German market. Sales to Germany will commence promptly upon the expected receipt of MedReleaf’s European Medical Agency Good Manufacturing Practices (“GMP”) certification and export permit from Health Canada in the coming weeks.

Germany is poised to become the largest federally regulated medical cannabis market in the world, with a population of over 82 million, approximately 89% of whom are covered by the public health insurance program and the remainder covered by private insurance plans. The current medical cannabis laws in Germany came into effect on March 10, 2017 and without domestic production, cannabis is being imported to meet the rapidly growing demand.

“Federally legal markets for cannabis outside Canada are by and large focused on medical applications. This plays to MedReleaf’s core strengths in R&D, innovation, quality control, and pharmaceutical grade standards,” said Neil Closner, President and CEO. “Medical cannabis in Germany has been in short supply and Cannamedical is an ideal partner to bring MedReleaf’s premium cannabis products into Germany as one of Europe’s leading cannabis distributors with shared values on patient-centricity, a proven track record, and a growing network of 1,800 pharmacies.”

“We are very much looking forward to supply all patients in need of medication with premium quality cannabis produced by the leading Canadian cannabis producer. Both companies have grown in a strong and excellent partnership to implement all German GMP standards in close collaboration.” said David Henn, CEO.

About MedReleaf Corp.

Voted Top Licensed Producer at the 2017 Lift Canadian Cannabis Awards, MedReleaf is an R&D-driven company dedicated to innovation, operational excellence and the production of top-quality cannabis. Sourced from around the world and carefully cultivated in one of two state of the art ICH-GMP and ISO 90001 certified facilities in Ontario, the Company delivers a variety of premium products for the global medical market and is committed to serving the therapeutic needs of its medical patients and providing a compelling product assortment for the adult-use recreational consumer.

For more information on MedReleaf, its products, research and how the company is helping patients #livefree, please visit or follow @medreleaf

About Cannamedical

Pioneering in the German cannabis industry, Cannamedical has been one of the first to specialize in highly efficient pharma distribution and marketing in accordance with the narcotics regulations. The privately-owned, GDP certified company holds all licenses required for medical cannabis import to Germany, distribution and export within the European Union. Cannamedical, as independent wholesaler has expertise in cannabis products and is serving an established and growing network of pharmacies all around the country.


On March 10th, 2018, the law “Cannabis as medicine” celebrates its first anniversary. For thousands of patients, the new law is a blessing. Thanks to the new law they benefit from the cannabis therapies which have to be paid by their health insurance companies. But not only from a health point of view does the cannabis law function like a European guidepost. A German company stands up for patients and is striving to ensure the European supply in the future.

The federal government had the courage to allow cannabis as medicine in Europe. Now it’s turning into a huge industry that will generate hundreds of new jobs and millions of euros in tax revenue in the near future.

At Cannamedical® Pharma GmbH, Germany´s leading independent cannabis wholesaler, 35 new permanent jobs were created for Cologne since the amendment of the law 12 months ago. And the potential is far from being exhausted. “We expect to create more than 350 new jobs within the next 24 months,” predicts David Henn, CEO of Cannamedical®

The independent wholesaler, based in Cologne, not only promotes better healthcare throughout Europe, but also offers innovative solutions to physicians and patients. Recently, Cannamedical® has entered a long-term partnership with one of Canada’s largest cannabis producers. “This partnership enables us to introduce up to 22 tons of high-quality cannabis to the European market by 2018,” says Niklas Kouparanis, the Sales Director of the company.

Last but not least, being based in Cologne is immensely important to Cannamedical® because of its cooperative supervisory authorities. The ongoing growth plans and the development of new sales markets could mean millions of euros for the city of Cologne in terms of tax revenues in the coming years.

Cannamedical® strives to strengthen the excellent cooperation between health insurance companies, importers and politicians in order to help Germany remain an internationally competitive business location and to improve the national job market.

“We are constantly reviewing production sites as we are looking to invest up to €20 million in a GMP-compliant, state-of-the-art manufacturing facility in the first expansion phase. In addition, Cannamedical® will invest another 10 million euros in cannabis research together with international partners over the next three years.

A large number of European countries have already created very attractive and inviting framework conditions for this, and another German location with comparable conditions could also be exciting. We are convinced that the cannabis agency will soon reach a decision regarding their public announcement on cannabis production from June 2017 and follow the example set by other European neighbors, “says Henn.

Download PDF

We’re here to help

Contact us

Our team of experts has a unique expertise and many years of professional experience.


Mo. – Fr. 8am-8pm
+49 221 / 999 852 – 00



Follow us

Social media

We are active on the
following platforms.

Ihr Warenkorb

0221 / 999 852 – 60

0221 / 999 852 – 25

Beratung dann, wenn es Ihnen passt: Einfach Termin auswählen und wir rufen Sie zur gewünschten Zeit zurück!
Unser Expertenteam steht Ihnen von Mo.–Fr. zwischen 8 und 20 Uhr zur Verfügung.

Ich bin ...